Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
In millions, except per share items | Oct-02-20 | Sep-27-19 | Sep-28-18 | Sep-29-17 | Sep-30-16 | Oct-02-15 | Sep-26-14 | Sep-27-13 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Revenues: |
Oncology Systems | 2,997.8 | 3,061.8 | 2,770.2 | 2,436.8 | 2,430.6 | 2,346.8 | 2,344.2 | 2,252.7 |
Varian Particle Therapy | 2,534.8 | 2,600.8 | 2,379.7 | 2,103.8 | 2,087.3 | 143.5 | | |
Transferred at Point in Time | 1,506.9 | 1,664.7 | 1,434.8 | 1,221.5 | 1,282.4 | | | |
Transferred over Time | 1,661.3 | 1,560.4 | 1,484.3 | 1,397.8 | 1,310.8 | | | |
Other | | | | | | | 705.6 | 690.2 |
Total revenues [+] | 3,168.2 | 3,225.1 | 2,919.1 | 2,619.3 | 2,593.7 | 2,490.7 | 3,049.8 | 2,942.9 |
Products | | | | | | 1,497.1 | 2,083.8 | 2,055.7 |
Services | | | | | | 993.6 | 966.0 | 887.2 |
Revenue growth [+] | -1.8% | 10.5% | 11.4% | 1.0% | 4.1% | -18.3% | 3.6% | 4.8% |
Oncology Systems | -2.1% | 10.5% | 13.7% | 0.3% | 3.6% | 0.1% | 4.1% | 2.9% |
Varian Particle Therapy | -2.5% | 9.3% | 13.1% | 0.8% | 1354.6% | | | |
Transferred at Point in Time | -9.5% | 16.0% | 17.5% | -4.7% | | | | |
Transferred over Time | 6.5% | 5.1% | 6.2% | 6.6% | | | | |
Other | 154.1% | | | | 25.0% | -99.1% | -6.0% | 30.2% |
Cost of goods sold [+] | 1,791.0 | 1,854.8 | 1,645.5 | 1,505.4 | 1,489.0 | 1,458.6 | 1,748.1 | 1,693.2 |
Cost of product sales | | | | | | 1,035.3 | 1,314.6 | 1,295.5 |
Cost of services | | | | | | 423.3 | 433.5 | 397.7 |
Gross profit | 1,377.2 | 1,370.3 | 1,273.6 | 1,113.9 | 1,104.7 | 1,032.1 | 1,301.7 | 1,249.7 |
Gross margin | 43.5% | 42.5% | 43.6% | 42.5% | 42.6% | 41.4% | 42.7% | 42.5% |
Selling, general and administrative | 671.8 | 623.1 | 543.5 | 552.8 | 472.2 | 441.0 | 470.6 | 432.6 |
Research and development | 280.6 | 247.6 | 233.9 | 210.0 | 200.4 | 195.4 | 234.8 | 208.2 |
Other operating expenses | 24.6 | 62.8 | 36.4 | 1.9 | | | | |
EBITDA [+] | 460.8 | 490.6 | 511.9 | 407.7 | 511.9 | 464.2 | 658.8 | 671.7 |
EBITDA growth | -6.1% | -4.2% | 25.6% | -20.4% | 10.3% | -29.5% | -1.9% | 2.5% |
EBITDA margin | 14.5% | 15.2% | 17.5% | 15.6% | 19.7% | 18.6% | 21.6% | 22.8% |
Depreciation | 22.4 | 26.5 | 31.5 | 58.5 | 64.2 | 60.1 | 57.7 | 58.5 |
EBITA | 438.4 | 464.1 | 480.4 | 349.2 | 447.7 | 404.1 | 601.1 | 613.2 |
EBITA margin | 13.8% | 14.4% | 16.5% | 13.3% | 17.3% | 16.2% | 19.7% | 20.8% |
Amortization of intangibles | 38.2 | 27.3 | 20.6 | | 15.6 | 8.4 | 4.8 | 4.3 |
EBIT [+] | 400.2 | 436.8 | 459.8 | 349.2 | 432.1 | 395.7 | 596.3 | 608.9 |
EBIT growth | -8.4% | -5.0% | 31.7% | -19.2% | 9.2% | -33.6% | -2.1% | 2.5% |
EBIT margin | 12.6% | 13.5% | 15.8% | 13.3% | 16.7% | 15.9% | 19.6% | 20.7% |
Non-recurring items [+] | 77.0 | 50.6 | 22.4 | 51.4 | 5.3 | | 25.1 | |
Asset impairment | 77.0 | 50.6 | 22.4 | 51.4 | 2.2 | | | |
Legal settlement | | | | | | | 25.1 | |
Interest income, net [+] | -3.6 | 6.3 | 10.5 | 2.9 | 5.6 | 5.6 | 3.3 | 3.2 |
Interest expense | 14.0 | 8.8 | 6.8 | 10.7 | 11.6 | 7.9 | 7.2 | 4.1 |
Interest income | 10.4 | 15.1 | 17.3 | 13.6 | 17.2 | 13.5 | 10.5 | 7.3 |
Other income (expense), net | 38.7 | 28.3 | 4.2 | 2.4 | | | | |
Pre-tax income | 358.3 | 420.8 | 452.1 | 303.1 | 432.4 | 401.3 | 574.5 | 612.1 |
Income taxes | 88.9 | 128.6 | 301.8 | 77.1 | 110.1 | 89.9 | 170.8 | 173.8 |
Tax rate | 24.8% | 30.6% | 66.8% | 25.4% | 25.5% | 22.4% | 29.7% | 28.4% |
Minority interest | 0.2 | 0.3 | 0.4 | | | 0.5 | | |
Earnings from continuing ops | 358.1 | 420.5 | 451.7 | 452.0 | 322.3 | 310.9 | 403.7 | 438.2 |
Earnings from discontinued ops | | | | -6.8 | 77.4 | 100.6 | | |
Net income | 358.1 | 420.5 | 451.7 | 445.2 | 399.7 | 411.5 | 403.7 | 438.2 |
Net margin | 11.3% | 13.0% | 15.5% | 17.0% | 15.4% | 16.5% | 13.2% | 14.9% |
|
Basic EPS [+] | $3.94 | $4.62 | $4.94 | $4.89 | $3.38 | $3.12 | $3.88 | $4.04 |
Growth | -14.7% | -6.4% | 1.0% | 44.6% | 8.3% | -19.7% | -4.0% | 5.5% |
Diluted EPS [+] | $3.91 | $4.58 | $4.88 | $4.85 | $3.36 | $3.09 | $3.83 | $3.98 |
Growth | -14.5% | -6.3% | 0.7% | 44.5% | 8.6% | -19.4% | -3.7% | 5.8% |
|
Shares outstanding (basic) [+] | 90.9 | 91.0 | 91.5 | 92.5 | 95.4 | 99.7 | 104.0 | 108.4 |
Growth | -0.1% | -0.5% | -1.1% | -3.0% | -4.3% | -4.1% | -4.0% | -2.7% |
Shares outstanding (diluted) [+] | 91.5 | 91.9 | 92.5 | 93.2 | 96.0 | 100.6 | 105.3 | 110.1 |
Growth | -0.4% | -0.6% | -0.8% | -2.9% | -4.6% | -4.5% | -4.3% | -3.0% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|